Efficacy and safety of glecaprevir/pibrentasvir in patients with hepatitis C virus infection aged ≥75 years.

Abstract

AIM:

Opportunities to treat older patients with hepatitis C virus infection have increased. We investigated the efficacy and safety of glecaprevir/pibrentasvir in patients with HCV infection aged ≥75 years.

METHODS:

We retrospectively evaluated 131 patients with hepatitis C virus infection treated with glecaprevir/pibrentasvir at nine institutions in Japan. The patients were divided into two groups according to their age: the elderly group (n = 43, aged ≥75 years) and younger group (n = 88, aged <75 years). We compared the clinical characteristics, virologic response and adverse events between the two groups. The predictive factors for adverse events were also assessed.

RESULTS:

The presence of cirrhosis (27.9%), a history of hepatocellular carcinoma (23.3%) and comorbidities (88.4%) were more frequently observed in the elderly group than in the younger group. Six (14.0%) patients in the elderly group and 19 (21.6%) in the younger group dropped out before the sustained virologic response 12 assessment. In the intention-to-treat population, 86.0% in the elderly group and 78.4% in the younger group achieved sustained virologic response 12 (P = 0.30). In the modified intention-to-treat population, all patients achieved sustained virologic response 12. A total of 27.5% of patients experienced adverse events. The most frequently observed adverse events was pruritus, and was significantly associated with female sex, the presence of hemodialysis and serum albumin at baseline <4.0 g/dL.

CONCLUSION:

Glecaprevir/pibrentasvir therapy was effective and well tolerated, even in elderly patients with hepatitis C virus infection aged ≥75 years. Geriatr Gerontol Int 2020; ••: ••-••.

• Authors: Akiyoshi Kinoshita, Kazuhiko Koike, Yusuke Mizuno, Itsuro Ogata, Yutaro Kobayashi, Kiyoshi Hasegawa, Koichi Shiraishi, Hideo Yoshida, Ryo Nakata, Norie Yamada, Kiyomi Yasuda
• Journal: Geriatrics & gerontology international (Geriatr Gerontol Int) Vol. 20 Issue 6 Pg. 578-583 (Jun 2020) ISSN: 1447-0594 [Electronic] Japan
• PMID: 32267087 (Publication Type: Journal Article, Multicenter Study, Observational Study)
• Copyright: © 2020 Japan Geriatrics Society.

Chemical References

• Aminoisobutyric Acids
• Antiviral Agents
• Benzimidazoles
• Cyclopropanes
• Lactams, Macrocyclic
• Pyrrolidines
• Quinoxalines
• Sulfonamides
• pibrentasvir
• Proline
• Leucine
• glecaprevir

Topics

• Adult
• Aged
• Aged, 80 and over
• Aminoisobutyric Acids
• Antiviral Agents (therapeutic use)
• Benzimidazoles (therapeutic use)
• Cyclopropanes
• Drug Therapy, Combination
• Female
• Genotype
• Hepatitis C (drug therapy)
• Humans
• Japan
• Lactams, Macrocyclic
• Leucine (analogs & derivatives)
• Male
• Middle Aged
• Proline (analogs & derivatives)
• Pyrrolidines
• Quinoxalines (therapeutic use)
• Retrospective Studies
• Sulfonamides (therapeutic use)
• Treatment Outcome